Immune checkpoint inhibitors such as anti-PD-1 antibodies respond in 20%-30% of tumor patients, and some advanced patients even completely alleviate the disease or survive for a long time, which is an important milestone in tumor immunotherapy. However, most patients with tumors are ineffective in initial PD-1 antibody therapy, or secondary to drug resistance after initial treatment, and it is urgent to analyze the mechanism of drug resistance and develop new treatment strategies.
Recently, Professor Wang Lishun's team of Fudan University and Academician Chen Guoqiang's team of Shanghai Jiao Tong University used models such as intestinal bacteria to artificialize tumor-bearing mice, and found that the intestinal flora of healthy donor sources can enhance the effect of PD-1 antibodies in the treatment of tumors; while the lactic acid bacteria in the intestines of healthy donors have increased significantly, and are positively correlated with the tumor treatment effect of PD-1 antibodies; researchers have further obtained a variety of lactic acid bacteria from healthy donor intestinal lactic acid bacteria through fine isolation and screening, verified their effects one by one, and finally found a new strain . Lactobacillus paracasei (named L.paracasei-sh2020) has the strongest effect on enhancing PD-1 antibodies.
This strain is different from the previously reported intestinal bacteria such as Ackerman, Faecal Bacillus, bifidobacterium and other intestinal bacteria, and is a new strain that enhances the anti-tumor effect of PD-1 antibodies. The results were published in the internationally renowned academic journal Gut Microbes.
Pectin enhances the anti-tumor effect of PD-1 antibodies
This study is another discovery based on the anti-tumor effect of dietary fiber pectin enhanced PD-1 antibody by Wang Lishun's team. These series of findings may help some tumor patients overcome resistance to PD-1 antibodies and effectively prolong survival in patients.